Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc. Fundamental Analysis
Protagonist Therapeutics, Inc. (PTGX) shows moderate financial fundamentals with a PE ratio of 114.88, profit margin of 21.94%, and ROE of 6.86%. The company generates $0.2B in annual revenue with moderate year-over-year growth of 6.24%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 59.4/100 based on profitability, valuation, growth, and balance sheet metrics. The C grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze PTGX's fundamental strength across five key dimensions:
Efficiency Score
WeakPTGX struggles to generate sufficient returns from assets.
Valuation Score
ModeratePTGX shows balanced valuation metrics.
Growth Score
ModeratePTGX shows steady but slowing expansion.
Financial Health Score
ExcellentPTGX maintains a strong and stable balance sheet.
Profitability Score
ModeratePTGX maintains healthy but balanced margins.
Key Financial Metrics
Is PTGX Expensive or Cheap?
P/E Ratio
PTGX trades at 114.88 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, PTGX's PEG of -11.92 indicates potential undervaluation.
Price to Book
The market values Protagonist Therapeutics, Inc. at 8.17 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 191.54 times EBITDA. This signals the market has high growth expectations.
How Well Does PTGX Make Money?
Net Profit Margin
For every $100 in sales, Protagonist Therapeutics, Inc. keeps $21.94 as profit after all expenses.
Operating Margin
Core operations generate 9.09 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $6.86 in profit for every $100 of shareholder equity.
ROA
Protagonist Therapeutics, Inc. generates $6.54 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Protagonist Therapeutics, Inc. generates strong operating cash flow of $64.18M, reflecting robust business health.
Free Cash Flow
Protagonist Therapeutics, Inc. generates strong free cash flow of $62.46M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $1.00 in free cash annually.
FCF Yield
PTGX converts 1.23% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
114.88
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-11.92
vs 25 benchmark
P/B Ratio
Price to book value ratio
8.17
vs 25 benchmark
P/S Ratio
Price to sales ratio
24.71
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.02
vs 25 benchmark
Current Ratio
Current assets to current liabilities
13.05
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.07
vs 25 benchmark
ROA
Return on assets percentage
0.07
vs 25 benchmark
ROCE
Return on capital employed
0.03
vs 25 benchmark
How PTGX Stacks Against Its Sector Peers
| Metric | PTGX Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 114.88 | 29.43 | Worse (Expensive) |
| ROE | 6.86% | 800.00% | Weak |
| Net Margin | 21.94% | -20145.00% (disorted) | Strong |
| Debt/Equity | 0.02 | 0.30 | Strong (Low Leverage) |
| Current Ratio | 13.05 | 4.64 | Strong Liquidity |
| ROA | 6.54% | -17936.00% (disorted) | Weak |
PTGX outperforms its industry in 3 out of 6 key metrics, particularly excelling in Net Margin, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Protagonist Therapeutics, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
78997.43%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
249.95%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
286.51%
Industry Style: Defensive, Growth, Innovation
High Growth